Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma

Czech version

Authors: I. Krajsová
Authors‘ workplace: Dermatovenerologická klinika 1. LF UK a VFN v Praze
Published in: Klin Onkol 2015; 28(Supplementum 4): 56-63
Category: Specials
doi: https://doi.org/10.14735/amko20154S56

Overview

Over the past several years, many important changes in the treatment of metastatic melanoma have occurred. New treatment options have been discovered to exploit inhibition of immune checkpoints for promotion of antitumor immune response. Recent results of clinical studies with anti-CTLA‑ 4 and anti-PD‑ 1 monoclonal antibodies show the ability of immunotherapy to extend progression‑free survival and overall survival in patients with metastatic melanoma when compared to chemotherapy and other therapeutic methods. This article focuses on efficacy and safety of these immunotherapeutic approaches and considered biomarkers of tumor response.

Key words:
malignant melanoma – immunotherapy – ipilimumab – nivolumab – pembrolizumab – combined immunotherapy – biomarkers

I declare that, in connection with the above-mentioned contribution, which I am an author, I have a conflict of interest with the following companies: BMS, MSD, Novartis and Roche (consultations and lectures honorarias).

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
24. 7. 2015

Accepted:
10. 9. 2015

Sources

. Sullivan RJ, Fisher DE. Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am 2014; 28(3): 437– 453. doi: 10.1016/ j.hoc.2014.02.007.

2. Shindo M, Yoshid Y. Regulatory T cells and skin tumors. Recent Pat Inflamm Allergy Drug Discov 2010; 4(3): 249– 254.

3. Aris M, Barrio MM, Mordoh J. Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol 2012; 2012: 192719. doi: 10.1155/ 2012/ 192719.

4. Freeman‑ Keller M, Weber JS. Anti‑programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015; 7(1): 12– 21. doi: 10.1177/ 1758834014551747.

5. Rosenberg SA, Packard B, Aebersold PM et al. Immunotherapy of patients with metastatic melanoma using tumor infiltrating lymphocytes and interleukin 2. N Engl J Med 1988; 319(25): 1676– 1680.

6. Galluzzi L, Vacchelli E, Pedro PJ et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5(24): 12472– 12508.

7. Luke JJ, Ott PA. PD‑ 1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 2014; 6(6): 3479– 3492.

8. Trinh VA, Hagen B. Ipilimumab for advanced melanoma. J Oncol Pharm Practice 2012; 19(3): 195– 201. doi: 10.1177/ 1078155212459100.

9. Hodi FS, O‘Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711– 723. doi: 10.1056/ NEJMoa1003466.

10. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517– 2526. doi: 10.1056/ NEJMoa1104621.

11. Wolchok JD, Hodi FS, Weber JS et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291: 1– 13. doi: 10.1111/ nyas.12180.

12. Momtaz P, Park V, Panageas KS et al. Safety of infusing ipilimumab over 30 minutes. J Clin Oncol 2015; 33(30): 3454– 3458. doi: 10.1200/ JCO.2015.61.0030.

13. Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune‑related response criteria. Clin Cancer Res 2009; 15(23): 7412– 7420. doi: 10.1158/ 1078‑ 0432.CCR‑ 09‑ 1624.

14. Weber JS, Kähler KC, Hauschild A. Management of immune‑related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21): 2691– 2697. doi: 10.1200/ JCO.2012.41.6750.

15. Luke JJ, Ott PA. PD‑ 1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 2014; 6(6): 3479– 3492.

16. Mahoney KM, Freeman GJ, McDermott DF. The next immune‑ checkpoint inhibitors: PD‑ 1/ PD‑ L1 blockade in melanoma. Clin Ther 2015; 37(4): 764– 782. doi: 10.1016/ j.clinthera.2015.02.018.

17. Topalian SL, Hodi FS, Brahmer JR et al. Safety, aktivity and immune correlates of antiPD‑ 1 antibody in cancer. N Engl J Med 2012; 366(26): 2443– 2454. doi: 10.1056/ NEJMoa1200690.

18. Topalian SL, Sznol M, McDermott DF et al. Survival durable tumor remission and long term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32(10): 1020– 1030. doi: 10.1200/ JCO.2013.53.0105.

19. Weber SJ, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti‑CTLA‑ 4 treatment (CheckMate 037): a randomized, controlled, open label phase 3 trial. Lancet Oncol 2015; 16(4): 375– 384. doi: 10.1016/ S1470‑ 2045(15)70076‑ 8.

20. Robert C, Long VG, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320– 330. doi: 10.1056/ NEJMoa1412082.

21. Larkin J, Lao CD, Urba WJ et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild‑type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 2015; 1(4): 433– 440. doi: 10.1001/ jamaoncol.2015.1184.

22. Robert C, Ribas A, Wolchok JD et al. Anti‑programmed‑ death‑ receptor‑ 1 treatment with pembrolizumab in ipilimumab refractory advanced melanoma: a randomized dose‑comparison cohort of a phase 1 trial. Lancet 2014; 384(9948): 1109– 1117. doi: 10.1016/ S0140‑ 6736(14)60958‑ 2.

23. Robert C, Schachter J, Long VG et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521– 2532. doi: 10.1056/ NEJMoa1503093.

24. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator‑ choice chemotherapy for ipilimumab‑ refractory melanoma (Keynote‑ 002): a randomized, controlled, phase 2 trial. Lancet Oncol 2015; 16(8): 908– 918. doi: 10.1016/ S1470‑ 2045(15)00083‑ 2.

25. Wolchok JD, Kluger H, Callahan H et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2): 122– 133. doi: 10.1056/ NEJMoa1302369.

26. Larkin J, Chiarion‑ Sileni V, Gonzales R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23– 34. doi: 10.1056/ NEJMoa1504030.

27. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372(21): 2006– 2017. doi:1056/ NEJMoa1414428.

28. Gogas H, Ioannovich J, Dafni U et al. Prognostic signifikance of autoimmunity during treatment of melanoma with Interferon alfa. N Engl J Med 2006; 354(7): 709– 718.

29. Ku YG, Yuna J, Page DB et al. Single‑institution experience with ipilimumabem in advanced melanoma patients in the compassionate use setting. Lymfocyte count after 2 doses correlates with survival. Cancer 2010; 116(7): 1767– 1775. doi: 10.1002/ cncr.24951.

30. Mahoney MK, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology 2014; 28 (Suppl 3): 39– 48.

31. Eggermont AM, Chiaroni‑ Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high‑risk stage III melanoma(EORTC 18071): a randomized double‑blind, phase 3 trial. Lancet Oncol 2015; 16(5): 522– 530. doi: 10.1016/ S1470‑ 2045(15)70122‑ 1.